FUNDAMENTALS · Fundamentals · JP Healthcare

Rion (6823) Fundamentals 2026 — P/E 12.5x, Revenue Analysis | SniperIQ

Rion (6823) is a JP-listed Healthcare company in Medical - Specialties with a market capitalization of ¥42.0B, trading at ¥3405.00 on the JPX. This SniperIQ fundamentals page covers Rion's valuation (P/E 12.5x, P/B 1.2x), profitability (net margin 11.7%), revenue (¥28.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥42.0B
P/E (TTM)12.5x
Net Margin11.7%
Revenue (FY25)¥28.5B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Rion's market cap?

Rion (6823) has a market capitalization of approximately ¥42.0B, trading at ¥3405.00 on the JPX. Market cap moves with the live share price.

What is Rion's P/E ratio?

Rion's trailing twelve-month P/E ratio is 12.5x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Rion?

Rion runs a net profit margin of 11.7%, a gross margin of 49.1%, and an operating margin of 15.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Rion generate?

Rion reported revenue of ¥28.5B for fiscal year 2025, with net income of ¥3.3B and earnings per share (EPS) of 271.43. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Rion pay a dividend?

Rion offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Rion financially healthy?

Rion carries a debt-to-equity ratio of 0.00x and a current ratio of 5.43x, with a market beta of 0.64. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Rion a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Rion (6823) the key facts are: market cap ¥42.0B, P/E 12.5x, revenue ¥28.5B, 52-week range 2480-4160. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Rion's full fundamentals live

Get Rion's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: France Bed Holdings (7840) fundamentals · Novartis India (NOVARTIND) fundamentals · Artemis Medicare Services (ARTEMISMED) fundamentals · China Resources Sanjiu Medical & Pharmaceutical (000999) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons